Core Viewpoint - The A-share market is experiencing a historic moment with the Shanghai Composite Index recording a 14-day winning streak, while the Hong Kong market shows weakness, particularly in technology stocks. However, innovative drug ETFs are performing well, indicating strong investor interest in the healthcare sector [1][3][4]. ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has risen over 3%, marking three consecutive days of gains, while the overall market shows mixed results. The Pharmaceutical ETF (562050) also recorded three consecutive daily gains, indicating a strong performance in the pharmaceutical sector [1][3][4]. - The largest medical ETF in the market (512170) is approaching its six-month line, reaching a new 20-day high, reflecting positive momentum in the healthcare sector [1][3][4]. Sector Highlights - The pharmaceutical sector is significantly outperforming the broader market, with leading innovative drug companies like Rongchang Bio surging over 11%. The overall performance of the pharmaceutical ETF indicates a strong bullish sentiment among investors [3][4]. - The AI application sector is also gaining traction, with the Entrepreneurial Board AI ETF (159363) reaching a new high, supported by strong performance in AI hardware and applications [9][11]. Market Outlook - Huaxi Securities suggests that the current market dynamics indicate an early spring rally, maintaining a bullish outlook. Key investment themes include emerging growth sectors and opportunities arising from anti-involution trends, particularly in AI, robotics, and renewable energy [2][20]. - The outlook for the metals sector remains optimistic, driven by macroeconomic factors such as potential interest rate cuts by the Federal Reserve and strong demand in traditional and emerging industries [13][15]. Investment Recommendations - Analysts recommend focusing on sectors benefiting from policy support, such as AI computing chains, robotics, and domestic replacements, as well as sectors poised for price increases like chemicals and non-ferrous metals [2][20]. - The innovative drug and medical device sectors are highlighted as key areas for investment, with a focus on companies that are expected to maintain strong growth trajectories through 2026 [7][20].

Market Overview - The Hong Kong stock market experienced its first decline of the year on January 7, with the Hang Seng Index closing at 26,458.95 points, down 251.50 points, a decrease of 0.94% [1][2]. - The Hang Seng Tech Index also fell, closing at 5,738.52 points, down 86.74 points, a decline of 1.49% [2]. Sector Performance - The pharmaceutical and biotechnology sector saw significant gains, with Rongchang Biologics (HK09995) rising over 12%, and other companies like Kailaiying (HK06821) and Tigermed (HK03347) increasing by over 8% [5]. - Rongchang Biologics announced positive clinical trial data for its PD-1/VEGF bispecific antibody RC148, which showed promising efficacy and safety for treating non-small cell lung cancer [5]. - Kangfang Biologics received approval for an important update on its PD-1/VEGF bispecific antibody, indicating significant clinical benefits in treating advanced non-small cell lung cancer [7]. Investment Trends - Southbound funds continued to significantly increase their holdings in Hong Kong stocks, with a net purchase exceeding 9.1 billion HKD by the end of the trading day [8]. - Research from CICC suggests that the Hong Kong stock market is entering a recovery phase, driven by a weaker US dollar and improved domestic liquidity, with a positive outlook for the first half of 2026 [12]. - Guotai Junan Securities anticipates a second round of valuation recovery and performance resurgence in the Hong Kong market in 2026, recommending focus on technology, healthcare, and consumer sectors [12]. Analyst Ratings - Credit Lyonnais maintained a "Outperform" rating for WuXi AppTec, raising the target price to 143.4 HKD, citing expected growth from outsourcing demand and reduced policy uncertainty [10].

Market Overview - On January 7, Hong Kong's major stock indices showed a downward trend, with the Hang Seng Index closing at 26,458.95 points, down 0.94% [1] - The Hang Seng Tech Index also ended its previous week's gains, falling 1.49% to 5,738.52 points [1] - The market turnover exceeded HKD 276 billion, ending the upward momentum of the three major indices from the previous trading day [1] Sector Performance - The biopharmaceutical sector showed significant activity towards the end of the trading session, with notable gains in several stocks [1] - Rongchang Biopharmaceutical (09995.HK) rose over 12%, while 3SBio (01530.HK) and WuXi Biologics (02269.HK) closed with gains of over 7% and 5%, respectively [1] - Other sectors such as paper, non-ferrous metals, and coal also saw some individual stocks increase in value [1] Brokerages - In contrast, brokerage stocks faced pressure, with Guotai Junan International (01788.HK) declining over 5% [1] - Both China Merchants Securities (06099.HK) and Everbright Securities (06178.HK) also experienced declines of over 2% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 榮昌生物製藥（煙台）股份有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09995 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 208,581,239 | RMB | | 1 RMB | | 208,581,239 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 208,581,239 | RMB | | 1 RMB | | 208,581,239 | | 2. 股份分類 | 普通股 | 股份類別 | A ...

Core Insights - The biopharmaceutical sector experienced a rise of 0.61% on January 7, with Rongchang Biopharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4085.77, up 0.05%, while the Shenzhen Component Index closed at 14030.56, up 0.06% [1] Stock Performance - Rongchang Biopharmaceutical (688331) closed at 91.24, with a significant increase of 11.13%, and a trading volume of 129,800 shares, amounting to 1.134 billion yuan [1] - Other notable performers included Buyuan Biopharmaceutical (688765) with a closing price of 78.16, up 8.14%, and Aidi Pharmaceutical (688488) at 17.45, up 6.73% [1] - The overall trading volume and turnover for the biopharmaceutical sector indicated strong investor interest, with Rongchang Biopharmaceutical leading in both metrics [1] Capital Flow - The biopharmaceutical sector saw a net inflow of 158 million yuan from institutional investors, while retail investors experienced a net outflow of 163 million yuan [2] - The data indicates a mixed sentiment among different investor types, with institutional investors showing confidence in the sector [2][3] Individual Stock Capital Flow - Rongchang Biopharmaceutical had a net inflow of 128 million yuan from institutional investors, while retail investors showed a net outflow of approximately 50 million yuan [3] - Other companies like Ganli Pharmaceutical (603087) and Junshi Biosciences (688180) also experienced net inflows from institutional investors, indicating a trend of institutional support for select stocks within the sector [3]

港股创新药板块尾盘持续拉升，荣昌生物涨超13%，泰格医药、凯莱英涨超9%，药明生物、信达生物 涨超5%。 ...

Core Viewpoint - Rongchang Biopharma (09995) experienced a significant stock increase of over 11%, reaching HKD 90.15 with a trading volume of HKD 577 million, following the announcement of promising clinical trial data for its PD-1/VEGF bispecific antibody RC148 in treating non-small cell lung cancer [1] Group 1: Clinical Research and Drug Development - The clinical research data for RC148, both as a monotherapy and in combination therapy, demonstrated outstanding clinical efficacy and manageable safety, achieving a dual-pathway breakthrough [1] - Rongchang Biopharma's two innovative drugs have successfully been included in the 2025 National Medical Insurance Drug List for four indications [1] Group 2: Commercialization and Market Position - According to Zhongtai Securities, Rongchang Biopharma is accelerating its commercialization capabilities and is rapidly approaching the breakeven point through efficient operations and targeted investments [1] - The company’s drug, Vidisicimab, is proposed to be included as a breakthrough therapy for a new indication, in combination with trastuzumab and toripalimab for first-line treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma, which would mark its fourth breakthrough therapy designation if approved [1]

具体内容详见公司于2025年12月16日、2025年12月23日在上海证券交易所网站（www.sse.com.cn）披露 的《荣昌生物关于以集中竞价交易方式回购股份的预案》（公告编号：2025-055）、《荣昌生物制药 （烟台）股份有限公司关于以集中竞价交易方式回购股份的回购报告书》（公告编号：2025-058）。 二、回购股份的进展情况 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 荣昌生物制药（烟台）股份有限公司（以下简称"公司"）于2025年12月15日召开第二届董事会第三十二 次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》。同意公司使用自有资金 和/或自筹资金以集中竞价交易方式回购公司已发行的部分人民币普通股（A股）股票，拟回购资金总额 不低于人民币2,000万元（含）且不超过人民币4,000万元（含），回购的股份将在未来合适的时机用于 员工持股计划或股权激励，回购价格不超过人民币95元/股（含），回购股 ...

Core Viewpoint - Rongchang Biologics (688331.SH) has announced that as of December 31, 2025, the company has not yet initiated any share buybacks and will implement buybacks opportunistically based on market conditions [1] Summary by Category - **Company Actions** - The company has not started any share repurchase program as of the end of 2025 [1] - The implementation of the buyback will depend on market conditions during the repurchase period [1]

Core Viewpoint - Rongchang Biologics (09995) has announced that as of December 31, 2025, the company has not yet initiated any share buybacks [1] Group 1 - The company plans to implement share buybacks opportunistically based on market conditions during the buyback period [1] - The company will fulfill its information disclosure obligations in a timely manner regarding the progress of the share buyback [1] - The progress of the buyback will comply with legal regulations and the company's buyback plan requirements [1]